Jacobio Pharmaceuticals Group Co Ltd is an investment holding company whose subsidiaries are engaged in the in-house discovery and development of oncology therapies. The company focuses on developing first-in-class drugs targeting difficult-to-drug targets within six major tumor signaling pathways: KRAS, tumor immunity, tumor metabolism, P53, RB, and MYC. Its pipeline includes small molecules, antibody drugs, and next-generation antibody conjugates such as ATDC, ISAC, and AOC. Key products in development include the KRAS G12C inhibitor golerimogene (JAB-21822), the SHP2 inhibitor JAB-3312, the pan-KRAS inhibitor JAB-23E73, and the BET inhibitor JAB-8263. The company operates laboratories in Beijing, Shanghai, and Boston, utilizing proprietary induced allosteric drug discovery and iADC platforms. Jacobio has established strategic partnerships, including a global exclusive licensing agreement with AstraZeneca for JAB-23E73 and collaborations with Eli Lilly and other partners. The group was founded in 2015 and includes subsidiaries such as Beijing Jacobio, Jacobio US, Jacobio HK, and Jacomab.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage jacobiopharma.com
Sector Healthcare IR page jacobiopharma.com/cn/investor-relations
Tags
oncology, kras inhibitors, antibody drug conjugates, small molecule drugs, btk inhibitors, snp2 inhibitors, drug discovery, clinical development, Beijing Jacobio, Jacobio US, Jacobio HK, Jacomab, JAB-21822, JAB-3312, JAB-23E73, JAB-8263, JAB-BX600, Golerimogene
Press page —

Metrics

Valuation  
Market cap HK$ 3.23B
Market cap (USD) $ 411.636M
P/E 5.34
PEG —
P/BV 2.02
P/S 3.72
P/OCF 5.23
P/FCF —
Dividend yield —
Turnover / mcap 0.15%
Returns  
ROE -17.2%
ROI -16.9%
ROIC -14.3%
Profit margin -272.7%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 7.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -46.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 53.525M 155.708M 63.52M 95.746M 152.809M — —
Net profit -145.981M -155.709M -359.119M -371.861M -301.187M -1.514B -425.817M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 7.91 1.36 3.13 5.24 10.41 — —
Price performance 12m 4.97 -0.56 -0.44 -0.52 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Oct 29, 2026

BEIJING, China, Oct. 29, 2026 — Jacobio Pharma (1167.HK) today announced that an investigator-initiated Phase 1b/2 clinical study of JAB-3312 in combination with vincristine, irinotecan, and temozolomide (VIT) is being conducted in the United States in patients with relapsed or refractory malignant peripheral nerve sheath tumors (MPNST).

The study will evaluate the safety, tolerability, and preliminary antitumor activity of JAB-3312 in combination with VIT in patients with relapsed or refractory MPNST, exploring the therapeutic potential of this combination.

JAB-3312 is an allosteric SHP2 inhibitor independently developed by Jacobio. This study will further explore its potential in combination therapy and a new indication. Meanwhile, a Phase 3 trial of JAB-3312 in combination with glecirasib as a first-line treatment for patients with KRAS G12C-mutated non-small cell lung cancer is ongoing in China.

About Jacobio

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.

Prompts

Jacobio Pharmaceuticals Group Co Ltd (ticker 1167), listed in Hong Kong.

ETFs Holding Jacobio Pharmaceuticals Group Co Ltd

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 70,800 $ 37.25K Nov 16, 2026
AVSE 0.01% 47,100 $ 24.781K Nov 16, 2026
AVEM 0.00% 403,500 $ 212.296K Nov 16, 2026
AVES 0.00% 26,400 $ 13.89K Nov 16, 2026